PARP inhibitor olaparib as treatment for pancreatic cancer patients with BRCA gene mutations

Optimizing Treatment Strategies for Germline BRCA/PALB2 Mutant Pancreatic AdenocarcinomaПодробнее

APOLLO: olaparib in pancreatic cancer with a BRCA1/2 or PALB2 mutationПодробнее

Comprehensive HRR Panel over a BRCA 1/2 testing, What works best for PARP inhibitors?Подробнее

What's New in Prostate Cancer Treatment? by Heather Cheng, MD, PhDПодробнее

PARP Inhibitors For The Treatment & Prevention Of Hereditary Breast & Ovarian CancerПодробнее

Role of PARP Inhibitors in Prostate CancerПодробнее

What's New in Pancreatic Cancer Treatment by Kim Reiss Binder, MDПодробнее

WATCH NOW: Optimizing Solid Tumor Management with PARP InhibitionПодробнее

Webinar: Parp-Inhibitors and Prostate Cancer - Gotta Have a Mutation??? 06/29/2023Подробнее

Olaparib for BRCA Positive Pancreatic Cancer PatientsПодробнее

3/26/2021: Upfront Treatment of Advanced Ovarian Cancer; Ay, Now the Plot ThickensПодробнее

Managed Care Implications of the Expanding Role of PARP Inhibitors in OncologyПодробнее

Update on PARP inhibitors in Ovarian and Pancreatic CancerПодробнее

ACT Genomics Dinner Symposium | Moving from BRCA1/2 to HRD: Beyond Woman’s CancersПодробнее

Target Practice: Understanding How PARP Inhibitors Take Aim at DDR Mutations Across Solid TumorsПодробнее

ACTG Dinner Symposium Highlights | BRCA testing – old story, new opportunities | Dr Shaheenah DawoodПодробнее

Genetic Testing for Prostate Cancer: Advances and Considerations | Webinar | Ambry GeneticsПодробнее

PARP inhibitor shrinks tumors in pancreatic cancer patients with mutationsПодробнее

POLO: maintenance olaparib in BRCA1/2 metastatic pancreatic cancerПодробнее

2020 In Review: Olaparib & Rucaparib, FDA Approval | Ask a Prostate Expert, Mark Scholz, MDПодробнее